Psychedelic treatment outcomes
Upcoming SlideShare
Loading in...5
×
 

Psychedelic treatment outcomes

on

  • 452 views

 

Statistics

Views

Total Views
452
Views on SlideShare
452
Embed Views
0

Actions

Likes
0
Downloads
4
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • 76% of heroin-dependent subjects receiving Ibogaine treatment in studies taking place between 1962-1993 showed no withdrawal symptoms (Apler, et al., 1999).Ibogaine currently being used in twelve countries across six continents (excluding US) in treating addiction (Donnelly, 2011).
  • Patients receiving three psychedelic doses of ketamine showed a 50% sobriety rate after a one year follow-up compared to a 25% recovery rate for those using naltrexone (most popular option) (Krupitsy et al., 2007).

Psychedelic treatment outcomes Psychedelic treatment outcomes Presentation Transcript

  • A Review of the Literature
  •  Do psychedelics contribute to successful treatment outcomes in chemically- dependent subjects?
  •  “Mind-Manifesting” Bringing repressed information from within the mind forward as amplification of emotion virtual reality containing symbolism unique to the experiencer. (Osmond, 1957). Distorts sensory observation/ bypasses ego & related defenses diving straight into the contents of one’s unconscious mind (Mabit, 2007). New awareness gained-integrated into conscious life for improved functioning (Grinspoon & Doblin, 2001). Psychedelics have existed for tens of thousands of years. Shamanism as indigenous psychotherapy/Divination = Diagnosis (Metzner, 1998). Psychedelics as catalysts not symptom relievers (Grinspoon & Doblin, 2001).
  •  How does Ibogaine work? Anti-addictive properties (Alper, Lotsof, Geerte, Frenken, Luciano, & Bastiaans, 1999). Amelioration/Elimination of withdrawal (Alper et al., 1999). Used in drug/alcohol treatment facilities abroad (Ibogaine Federation, 2011). Not a substitution drug 9 fatalities in 20 years compare to methadone at 10,000 within a two year timespan (Donnelly, 2011).
  •  How does ketamine work? Ketamine therapy resulted in significantly higher rates of abstinence among heroin-dependent as compared to placebo and naltrexone (Krupitsky, Burakov, Dunaevsky, Romanova, Slavina, and Grinenko, 2002, 2007). Faster acting than anti-depressants in treating depressive symptoms in recovering patients (Krupitsky et al., 2007). More ketamine doses = higher recovery rates (Krupitsky et al., 2007). Not a substitution drug but potentially addictive. Quick, safe, cost-effective (Krupitsky et al., 2007).
  •  What is LSD? MDMA? Social research, Anecdotal evidence: 40 y.o. male 4 years alcoholism, experiences breakthrough under the influence of LSD involvingChristian symbolism (Grinspoon & Doblin, 2001). Psychedelic experience serves to make manifest the symbols/contents of an individuals mind, hallucinations not random. MDMA used to dissolve ego-defenses in psychotherapy, Switzerland (Grinspoon & Doblin, 2001). MDMA con: potentially addictive
  •  Cross-cultural study showed subjects who have had peak psychedelic experiences have no better coping abilities or resiliency than those who had not (Recreational not treatment) (Lerner & Lyvers, 2006). Anthropological study notes East believes psychedelic experience real as West believes it merely to be a hallucination (Metzner, 1998). Guide experiences treatment with client in East/Indigenous cultures whereas guide in West typically does not (Metzner, 1998). Integration of East & West in psychedelic treatment (Metzner, 1998).
  •  Yes psychedelics can contribute to successful treatment outcomes depending on “set” (intentions, expectations, & motivations) of user and “setting” (environment surrounding user at time of drug experience including person(s) involved. How do we better control for “set” and “setting”? Set - better psych assessments, bibliotherapy. Setting - more relaxed, less clinical environment.
  • Psychedelic merely acts as vehicle to make repressed contents of mindvisible. A bringer of awareness, messenger drug. It is up to the individual tomake the choice post-psychedelic experience to integrate this newawareness into their conscious life.How do we empower people? How do we honor the individual process? Psychedelic experience deeply personal. Psychedelic allows one to bypass ego/conscious patterns of thought and behavior and dive straight into the contents of the unconscious mind leading to expanded awareness (Mabit, 2007). How do you measure something like this? A new set of principles for exploring inner-landscape? Controlled experimentation gives way to consciousness exploration ?…
  •  Alper, K.R., Lotsof, H.S., Geerte, M., Franken, N., Luciano, D.J. & Bastiaans, J. (1999). Treatment of acute opioid withdrawal with ibogaine. The American Journal on Addictions. 8, 234-242. Donnelly, Jennifer R. (2011). The need for ibogaine in drug and alcohol addiction treatment. Journal of Legal Medicine. 32, 93-114. Grinspoon, L., Doblin, R. (2001). Psychedelics as catalysts of insight-oriented psychotherapy. Social Research. 68, 677-696. Kupritsky, E.M., Burakov, A.M., Dunaevsky, I.V., Romanova, T.N., Slavina, T.Y., & Grinenko, A.Y. (2002). Ketamine psychotherapy for heroin addiction: immediate effects and two year follow-up. Journal of Substance Abuse Treatment. 23, 273-283. Kupritsky, E.M., Burakov, A.M., Dunaevsky, I.V., Romanova, T.N., Slavina, T.Y., & Grinenko, A.Y. (2007). Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin-dependence. Journal of Psychoactive Drugs. 39, 381-418. Lerner, M., Lyvers, M. (2006). Values and beliefs of psychedelic drug users: A cross-cultural study. Journal of Psychoactive Drugs. 38, 143-147. Mabit, J. (2007). Ayahuasca in the treatment of addictions. Psychedelic Medicine. 2, 87-103. Mangini, M. (1998). Treatment of alcoholism using psychedelic drugs: A review of the program of research. Journal of Psychoactive Drugs. 30, 381-418. Metzner, R. (1998). Hallucinogenic drugs and plants in psychotherapy and shamanism. Journal of Psychoactive Drugs. 30, 333-341. United States Department of Health and Human Services. (2011). The Facts About Naltrexone for Treatment of Opioid Addiction. [Brochure]. Retrieved December 3, 2011, from http://kap.samhsa.gov/products/brochures/pdfs/naltrexone_facts.pdf. What is Ibogaine? (2011). International Federation of Ibogaine Providers. Retieved December 11, 2011, from http://www.ibogainefederation.org/index.php?id=273. Leary, T., Alpert, R., Metzner, R. (2001). The Psychedelic Experience. New York, New York: Kensington Publishing Corp.